SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Cash from Financing Activities data on file, last reported at $44.2 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $44.2 million, up 87.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.9 million (up 144.58% YoY), and the FY2025 annual result was $86.3 million, up 84.56% from the prior year.
• Cash from Financing Activities climbed to $44.2 million in Q1 2026 per SLS's latest filing, from $32.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $44.2 million in Q1 2026 and troughed at -$29000.0 in Q2 2023.
• A 5-year average of $13.2 million and a median of $4.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 100.13% in 2023, then soared 404825.0% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $929000.0 in 2022, then surged by 264.48% to $3.4 million in 2023, then tumbled by 99.76% to $8000.0 in 2024, then soared by 404825.0% to $32.4 million in 2025, then jumped by 36.29% to $44.2 million in 2026.
• Business Quant data shows SLS's Cash from Financing Activities at $44.2 million in Q1 2026, $32.4 million in Q4 2025, and $26.1 million in Q3 2025.